Eisai Co., Ltd.: Neoplasms trials

The registry lists 33 Neoplasms studies with Eisai Co., Ltd. as lead sponsor. 2 are open to participants now and 14 have results posted.

Phase 1 30Phase 2 7No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyRecruitingNCT06793709
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingNCT04300556Phase 1/2
• Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT03006887Phase 1Results posted
• Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid TumorsCompletedNCT02686164Phase 1Results posted
• Study of E7046 in Subjects With Selected Advanced MalignanciesTerminatedNCT02540291Phase 1Results posted
• A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT02501096Phase 1/2Results posted
• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With OsteosarcomaCompletedNCT02432274Phase 1/2Results posted
• Phase 1 Study of E7090 in Subjects With Solid TumorCompletedNCT02275910Phase 1Results posted
• An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid TumorsCompletedNCT01945710Phase 1Results posted
• An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid TumorsCompletedNCT01773421Phase 1Results posted
• Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV MelanomaCompletedNCT01127451Phase 2Results posted
• Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid TumorsTerminatedNCT01127178Phase 1Results posted
• QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid TumorsCompletedNCT01106248Phase 1Results posted
• A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid TumorsCompletedNCT00908908Phase 1Results posted
• An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid TumorsCompletedNCT00280397Phase 1Results posted
• Study of E7389 in Patients With Advanced Solid TumorsCompletedNCT00069264Phase 1Results posted
• A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorActive, not recruitingNCT04078295Phase 1/2
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Phase 1/2
• A Study of Overall Survival in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT04008082
• A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid TumorsCompletedNCT03386942Phase 1
• Study of E7386 in Participants With Selected Advanced NeoplasmsActive, not recruitingNCT03264664Phase 1
• Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid TumorCompletedNCT03009292Phase 1
• To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid TumorsCompletedNCT03002493Phase 1
• A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)CompletedNCT01773434Phase 1
• MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
• An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01618136Phase 1/2
• A Phase I Study of E7050 in Subjects With Solid TumorsCompletedNCT01428141Phase 1
• A Study of MORAb-003 in Patients With Solid TumorCompletedNCT01049061Phase 1
• A Study of E7050 Administered Orally to Patients With Advanced Solid TumorsCompletedNCT00921869Phase 1
• A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid TumorsCompletedNCT00794781Phase 1
• A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid TumorsCompletedNCT00165802Phase 1
• A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid MalignanciesCompletedNCT00130169Phase 1
• An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid MalignanciesCompletedNCT00121732Phase 1